- Home
- ORGO vs KROS Comparison
ORGO vs KROS Comparison
Compare ORGO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- KROS
- Stock Information
- Founded
- ORGO 1985
- KROS 2015
- Country
- ORGO United States
- KROS United States
- Employees
- ORGO N/A
- KROS N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ORGO Health Care
- KROS Health Care
- Exchange
- ORGO Nasdaq
- KROS Nasdaq
- Market Cap
- ORGO 620.3M
- KROS 565.0M
- IPO Year
- ORGO N/A
- KROS 2020
- Fundamental
- Price
- ORGO $4.90
- KROS $15.52
- Analyst Decision
- ORGO Buy
- KROS Buy
- Analyst Count
- ORGO 2
- KROS 14
- Target Price
- ORGO $7.50
- KROS $20.56
- AVG Volume (30 Days)
- ORGO 761.1K
- KROS 430.7K
- Earning Date
- ORGO 11-11-2025
- KROS 11-05-2025
- Dividend Yield
- ORGO N/A
- KROS N/A
- EPS Growth
- ORGO N/A
- KROS N/A
- EPS
- ORGO N/A
- KROS 0.47
- Revenue
- ORGO $429,531,000.00
- KROS $232,844,000.00
- Revenue This Year
- ORGO $2.57
- KROS $5,579.44
- Revenue Next Year
- ORGO $9.80
- KROS N/A
- P/E Ratio
- ORGO N/A
- KROS $33.65
- Revenue Growth
- ORGO N/A
- KROS 85820.30
- 52 Week Low
- ORGO $2.48
- KROS $9.12
- 52 Week High
- ORGO $6.71
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ORGO 52.77
- KROS 58.11
- Support Level
- ORGO $4.75
- KROS $15.23
- Resistance Level
- ORGO $5.10
- KROS $15.85
- Average True Range (ATR)
- ORGO 0.21
- KROS 0.48
- MACD
- ORGO -0.02
- KROS -0.01
- Stochastic Oscillator
- ORGO 39.39
- KROS 68.56
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.